Imaging Biometrics Acquires Kirkstall in Strategic Biotech Expansion

The CLN: mechanics, conversion and what it means for dilution

A Convertible Loan Note is debt that can turn into equity. Here’s what matters:

• 6% interest accrues and is added to the balance until conversion or redemption.
• It is unsecured and subordinated, meaning it sits behind other creditors if something goes wrong.
• Conversion is at Truetide’s discretion at the lower of £0.075 (subject to a General Meeting to change the Company’s par value) or the price of any fundraising completed prior to conversion.
• Conversion cannot proceed if it would take Truetide and any concert parties to 30% or more of IBAI’s issued share capital (as enlarged by the conversion).

Why this matters: the “lower of” clause means that if IBAI raises equity at a lower price than £0.075, the CLN could convert at that fundraising price. That increases potential dilution compared with a fixed higher price. On the flip side, the 30% safeguard prevents creeping control via conversion.

Related party transaction: governance steps taken

This is a related party transaction under DTR 7.3 because Truetide holds 29.35% of IBAI and Trevor Brown is an executive director of both companies (and holds 27.99% of Truetide). In such cases, independent directors must scrutinise the deal.

The independent directors – Dr Al Musella, Brett Skelly and Michael Schmainda – assessed the SPA and CLN and consider them fair and reasonable for the Company and for shareholders who are not a related party. Trevor Brown recused himself from all deliberations. The RNS stresses compliance with governance standards and shareholder protections.

Strategic read-through: a small bolt-on with US upside

At £170,000 for 100% of Kirkstall, this is a small bolt-on acquisition. That size can be a feature, not a bug, if the underlying product has leverage into larger markets. Quasi Vivo sits in a sweet spot where academic research meets pharma R&D, and the US is a logical next step.

IBAI’s assertion that it has the market knowledge and expertise to support US growth is the strategic hinge here. If the company can help translate the QV1200’s technical credibility into commercial momentum stateside, the return on a relatively modest consideration could be attractive. The CLN structure keeps cash demands low today, albeit with potential equity dilution later.

The positives and the watch-outs

What looks positive

• Cash-light deal using an unsecured, subordinated CLN preserves cash.
• Clear route to 100% ownership via drag-along provisions.
• Product-market fit: QV1200 addresses a clear need for more physiologically relevant models.
• Early signs of sales growth and an explicit push into the US market.
• Independent directors have assessed the related party terms as fair and reasonable.

What to keep an eye on

• Dilution risk from CLN conversion, especially if future fundraisings are priced below £0.075.
• Execution in the US – the RNS does not disclose a US partner or a go-to-market plan (not disclosed).
• Integration and scaling – no financials for Kirkstall are provided (not disclosed), so the growth base is unclear.
• Par value considerations – the £0.075 conversion price is subject to a General Meeting to change the Company’s par value.

What happens next

Mechanically, expect IBAI to complete on the 86.11% stake and then use the drag-along provisions to move to 100% ownership. The CLN runs to 31 December 2027, so conversion, redemption or any intervening fundraise will be key milestones.

Commercially, watch for updates on US distribution or partnerships for QV1200, evidence of sales momentum beyond UK academia, and any shareholder actions related to par value changes. With governance boxes ticked for this related party transaction, the focus now turns to execution.